Cancer survivorship - heart failure risk factor or potentiator?

Abstract Introduction An emerging challenge in cancer survivorship is the increased incidence of heart failure (HF) in long term adult survivors. This has been attributed to shared risk factors found between cancer and HF, cancer treatment-related cardiac dysfunction (CTRCD) and cancer itself. However, determining the magnitude and interplay of these risks can refine the process of risk-stratifying which survivors are most vulnerable to the development of HF. Objective This study investigates the relationship between traditional HF risk factors and subclinical HF (Stage B/SBHF) in adult cancer survivors compared to non-cancer controls. Methods 102 adult survivors ≥10 years post cardiotoxic cancer treatment were prospectively recruited. All participants were evaluated with clinical review and echocardiography for presence of SBHF. SBHF was defined as the presence of left ventricular hypertrophy, abnormal global longitudinal strain (GLS) or diastolic dysfunction. Participants were matched to non-cancer controls by traditional HF risk factors - hypertension (HTN), type-2 diabetes (T2DM), obesity and age. Participants were excluded if they were symptomatic, had a prior history of HF or moderate/severe valvular regurgitation. Results Approximately 50% of cancer survivors did not have any of the 3 main HF risk factors (HTN, T2DM, obesity). The mean ARIC-HF 4-year risk score in cancer survivors was 3.1% [1.8, 5.6]. When matched by HF risk factors (HTN, T2DM, obesity and age), there was no difference in SBHF prevalence and GLS between cancer survivors (38%, -18.7%) and non-cancer controls (43%, -18.7%, (SBHF p=0.53%, GLS p=0.92%). However, the association between HF risk factors and impaired GLS (<-16%) was stronger in cancer survivors compared to non-cancer controls (Table 1). Conclusion Our investigation indicates that cancer survivorship alone may not directly contribute to the development of SBHF. However, it appears to exert a synergistic influence when coupled with established risk factors such as HTN, T2DM or obesity, potentially exacerbating the progression of SBHF.Table 1:HF risk factors & abnormal GLS

Authors

Institutions

Publication Details

Journal
European Heart Journal
Published
2024-10-01
DOI
https://doi.org/10.1093/eurheartj/ehae666.1014
Citations
1
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cancer survivorship - heart failure risk factor or potentiator?

Quan Huynh, Joshua Wong, Thomas H. Marwick, Julian A. Smith et al.
1 citations
European Heart Journal
Chemotherapy-induced cardiotoxicity and mitigation
0.40
article

Cancer survivorship - heart failure risk factor or potentiator?

Quan Huynh, Joshua Wong, Thomas H. Marwick, Julian A. Smith, C. Soh
article en
1 citations

Abstract

Abstract Introduction An emerging challenge in cancer survivorship is the increased incidence of heart failure (HF) in long term adult survivors. This has been attributed to shared risk factors found between cancer and HF, cancer treatment-related cardiac dysfunction (CTRCD) and cancer itself. However, determining the magnitude and interplay of these risks can refine the process of risk-stratifying which survivors are most vulnerable to the development of HF. Objective This study investigates the relationship between traditional HF risk factors and subclinical HF (Stage B/SBHF) in adult cancer survivors compared to non-cancer controls. Methods 102 adult survivors ≥10 years post cardiotoxic cancer treatment were prospectively recruited. All participants were evaluated with clinical review and echocardiography for presence of SBHF. SBHF was defined as the presence of left ventricular hypertrophy, abnormal global longitudinal strain (GLS) or diastolic dysfunction. Participants were matched to non-cancer controls by traditional HF risk factors - hypertension (HTN), type-2 diabetes (T2DM), obesity and age. Participants were excluded if they were symptomatic, had a prior history of HF or moderate/severe valvular regurgitation. Results Approximately 50% of cancer survivors did not have any of the 3 main HF risk factors (HTN, T2DM, obesity). The mean ARIC-HF 4-year risk score in cancer survivors was 3.1% [1.8, 5.6]. When matched by HF risk factors (HTN, T2DM, obesity and age), there was no difference in SBHF prevalence and GLS between cancer survivors (38%, -18.7%) and non-cancer controls (43%, -18.7%, (SBHF p=0.53%, GLS p=0.92%). However, the association between HF risk factors and impaired GLS (<-16%) was stronger in cancer survivors compared to non-cancer controls (Table 1). Conclusion Our investigation indicates that cancer survivorship alone may not directly contribute to the development of SBHF. However, it appears to exert a synergistic influence when coupled with established risk factors such as HTN, T2DM or obesity, potentially exacerbating the progression of SBHF.Table 1:HF risk factors & abnormal GLS

European Heart JournalVol. 45(Supplement_1)
Baker Heart and Diabetes Institute (AU)
Openalex Percentile: Top 32%
Chemotherapy-induced cardiotoxicity and mitigation
0.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.